{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:35:58Z","timestamp":1778567758503,"version":"3.51.4"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute, USA","doi-asserted-by":"publisher","award":["P30 CA014089"],"award-info":[{"award-number":["P30 CA014089"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute, USA","doi-asserted-by":"publisher","award":["U01-CA-151837"],"award-info":[{"award-number":["U01-CA-151837"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute, USA","doi-asserted-by":"publisher","award":["R01CA-154471"],"award-info":[{"award-number":["R01CA-154471"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute, USA","doi-asserted-by":"publisher","award":["R21-CA-164098"],"award-info":[{"award-number":["R21-CA-164098"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute, USA","doi-asserted-by":"publisher","award":["P30 CA16672"],"award-info":[{"award-number":["P30 CA16672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004412","name":"Turkish Academy of Sciences, Turkey","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ebiom.2018.12.004","type":"journal-article","created":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T19:00:43Z","timestamp":1544468443000},"page":"612-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma"],"prefix":"10.1016","volume":"39","author":[{"given":"Fatih M.","family":"Uckun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjive","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taner","family":"Demirer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2018.12.004_bb0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0010","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2016.70.6705","article-title":"Genomics of multiple myeloma","volume":"35","author":"Robiou du Pont","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-018-0103-3","article-title":"Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms","author":"Hoang","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0020","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2018.12.004_bb0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3324\/haematol.2017.174573","article-title":"From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives","volume":"103","author":"Gay","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.ebiom.2018.12.004_bb0030","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.clml.2018.06.015","article-title":"The multiple myeloma drug pipeline 2018: A review of small molecules and their therapeutic targets","volume":"18","author":"Abramson","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2018.06.018","article-title":"Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study","author":"Mohty","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.ebiom.2018.12.004_bb0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17474086.2018.1437345","article-title":"The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe","volume":"11","author":"Cavo","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0045","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood-2015-06-653261","article-title":"How I treat high-risk myeloma","volume":"126","author":"Lonial","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ebiom.2018.12.004_bb0050","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/bjh.15058","article-title":"Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results","volume":"180","author":"Richardson","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.ebiom.2018.12.004_bb0055","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1073\/pnas.0909086107","article-title":"STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia\/lymphoma cells exposed to oxidative stress","volume":"107","author":"Uckun","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.ebiom.2018.12.004_bb0060","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/j.clml.2018.06.003","article-title":"Venetoclax in Combination with Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma","volume":"18","author":"Rahbari","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0065","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/leu.2015.208","article-title":"Inhibiting MEK in MAPK pathway-activated myeloma","volume":"30","author":"Heuck","year":"2016","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.ebiom.2018.12.004_bb0070","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40164-015-0016-z","article-title":"Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma","volume":"4","author":"Koerber","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2018.12.004_bb0080","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/0008-5472.CAN-14-2362","article-title":"Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.ebiom.2018.12.004_bb0085","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood.V130.Suppl_1.741.741","volume":"130","author":"Trudel","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ebiom.2018.12.004_bb0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.15116","article-title":"Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma","volume":"181","author":"Varga","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ebiom.2018.12.004_bb0095","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0100","author":"Jain","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1016\/j.ebiom.2018.12.004_bb0105","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/bloodadvances.2018017186","article-title":"Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM","volume":"2","author":"Jagannath","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0110","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART) consensus statement","author":"Gonsalves","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0115","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.2961","article-title":"Maintenance Treatment and Survival in patients with Myeloma: a Systematic Review and Network Meta-analysis","author":"Gay","year":"2018","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.ebiom.2018.12.004_bb0120","first-page":"564","article-title":"The evolving role of\u00a0transplantation\u00a0in\u00a0multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease","volume":"16","author":"Gandolfi","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.6004\/jnccn.2018.0002","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2018","volume":"16","author":"Kumar","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"18","key":"10.1016\/j.ebiom.2018.12.004_bb0130","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1002\/cncr.30770","article-title":"Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma","volume":"123","author":"Veltri","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0135","series-title":"JCO precision oncology","article-title":"Precision medicine for relapsed multiple myeloma on the basis of an integrative multiomics approach","author":"Lagana","year":"2018"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0140","article-title":"Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-Centre phase I\/II Clinical Trial)","author":"Popat","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0145","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.15504","article-title":"Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients","author":"Oostvogels","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13147","article-title":"Bortezomib-based therapy for relapsed\/refractory multiple myeloma in real-world medical practice","author":"Terpos","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0155","doi-asserted-by":"crossref","DOI":"10.1080\/17474086.2018.1518129","article-title":"Ixazomib: a novel drug for multiple myeloma","author":"Zanwar","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"10.1016\/j.ebiom.2018.12.004_bb0160","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2018.12.004_bb0165","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/leu.2017.258","article-title":"Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial","volume":"32","author":"Ailawadhi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ebiom.2018.12.004_bb0175","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","article-title":"How I treat first relapse of myeloma","volume":"130","author":"Harousseau","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ebiom.2018.12.004_bb0180","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ebiom.2018.12.004_bb0185","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (a.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2018.12.004_bb0190","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/1744666X.2018.1443809","article-title":"CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience","volume":"14","author":"Frerichs","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2018.12.004_bb0195","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0200","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.ebiom.2018.12.004_bb0205","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon-2017-0616","article-title":"Isatuximab plus pomalidomide\/dexamethasone versus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma: ICARIA phase III study design","volume":"14","author":"Richardson","year":"2018","journal-title":"Future Oncol"},{"issue":"22","key":"10.1016\/j.ebiom.2018.12.004_bb0210","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/blood.V128.22.1152.1152","article-title":"A phase I\/IIa Study of the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma","volume":"128","author":"Raab","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0215","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-018-3469-4","article-title":"Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study","author":"Cella","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.31680","article-title":"Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended 4-year follow-up and Analysis of relative progression-free survival from the randomized ELOQUENT-2 trial","author":"Dimopoulos","year":"2018","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.ebiom.2018.12.004_bb0225","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0230","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.ebiom.2018.12.004_bb0235","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2018.06.012","article-title":"CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma","volume":"26","author":"Bluhm","year":"2018","journal-title":"Mol Ther"},{"issue":"15","key":"10.1016\/j.ebiom.2018.12.004_bb0240","article-title":"First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: Updated results","volume":"35","author":"Jesus","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0245","series-title":"ASCO Annual Meeting. Abstract LBA3001. Presented June 5, 2017","article-title":"Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory\/relapsed multiple myeloma","author":"Fan","year":"2017"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0250","article-title":"The future of chimeric antigen receptor T cell therapy for the treatment of Multiple Myeloma","author":"Cornell","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0255","article-title":"Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in Multiple Myeloma","author":"D'Agostino","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02431","article-title":"Update on PD-1\/PD-L1 inhibitors in Multiple Myeloma","author":"Jelinek","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0265","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cellimm.2018.10.003","article-title":"The challenges of checkpoint inhibition in the treatment of multiple myeloma","volume":"334","author":"Paul","year":"2018","journal-title":"Cell Immunol"},{"issue":"2","key":"10.1016\/j.ebiom.2018.12.004_bb0270","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamaoncol.2015.4701","article-title":"Palbociclib (PD0332991)-a selective and potent cyclin-dependent kinase inhibitor: a review of pharmacodynamics and clinical development","volume":"2","author":"Clark","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0275","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00070","article-title":"Vemurafenib in patients with relapsed refractory Multiple Myeloma harboring BRAFV600 Mutations: a Cohort of the histology-independent VE-BASKET study","author":"Raje","year":"2018","journal-title":"JCO Precision Oncol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0280","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/blood-2015-12-686782","article-title":"Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition","volume":"127","author":"Raab","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ebiom.2018.12.004_bb0285","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ebiom.2018.12.004_bb0290","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ajh.23433","article-title":"Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease","volume":"88","author":"Bam","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0295","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ebiom.2018.12.004_bb0300","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone marrow microenvironment\u2013derived signals induce Mcl-1 dependence in multiple myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0305","series-title":"Proceedings of the American Association for Cancer Research Annual Meeting 2017","article-title":"Alvocidib potentiates the activity of venetoclax in preclinical models of multiple myeloma [abstract]","volume":"77(13 Suppl)","author":"Livingston","year":"2017"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0310","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/leu.2015.350","article-title":"Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ebiom.2018.12.004_bb0315","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0320","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.189159","article-title":"An European Myeloma network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when","author":"Caers","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0325","first-page":"1","article-title":"High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes","author":"Hu","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0330","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25279","article-title":"Utility and Prognostic Value of 18 F-FDG Positron Emission Tomography-Computed Tomography Scans in patients with newly Diagnosed Multiple Myeloma","author":"Aljama","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0335","article-title":"18F-FDG PET\/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the revised international staging system","author":"Jung","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0340","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-0741","article-title":"Interim PET analysis in first line therapy of multiple myeloma: Prognostic value of \u0394SUVmax in the FDG-avid patients of the IMAJEM study","author":"Bailly","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ebiom.2018.12.004_bb0345","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","article-title":"Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)","volume":"103","author":"Bringhen","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.critrevonc.2018.07.003","article-title":"Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: a pooled analysis","volume":"130","author":"Bringhen","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0355","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ebiom.2018.12.004_bb0360","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1080\/10428194.2016.1250263","article-title":"Plasma cell leukemia: update on biology and therapy","volume":"58","author":"Mina","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ebiom.2018.12.004_bb0365","first-page":"10(453)","article-title":"Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)","volume":"8","author":"Rashid","year":"2018","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.ebiom.2018.12.004_bb0370","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.2017.9991","article-title":"Multidimensional evidence Generation and FDA Regulatory Decision making: defining and using \"Real-World\" Data","volume":"318","author":"Jarow","year":"2017","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.ebiom.2018.12.004_bb0375","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396418305759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396418305759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:51:31Z","timestamp":1762455091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396418305759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":75,"alternative-id":["S2352396418305759"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.004","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}